Partner Ventures
3130 Alpine Road Suite 288/115, Portola Valley, CA, 94028, United States
Overview
Partner Ventures is a 'secondary direct' venture capital fund. We provide liquidity to preferred stockholders of excellent companies, typically taking a seat on the company's Board of Directors. We work collaboratively with portfolio company management and board to help achieve its growth, profitability and liquidity objectives.
- Total investments
- 3
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 2
Investment portfolio
- Cereve
Participated · Series B · Jan 2017
Cereve develops an FDA-cleared, drug-free insomnia therapy system consisting of an intelligent bedside device that precisely cools and pumps fluid to a forehead pad worn throughout the night. Three independent clinical studies on more than 230 patients across 3,800 research nights demonstrated the safety and efficacy of the device, and subjects reported it was easy to use and comfortable. The company holds eight issued and 21 pending patents covering the Cereve System. Cereve was formed in 2008 and is based near Pittsburgh, PA. It is preparing for a U.S. market launch in the second half of 2017 and plans to deploy new funding to build out infrastructure and support rapid expansion to meet physician and patient demand. Management includes executives with sleep-sector experience from Respironics.
- Partner Ventures
Participated · Series B · Jan 2017
Cerêve develops an FDA-cleared bedside system that precisely cools and pumps fluid to a forehead pad worn throughout the night to treat insomnia. Three independent clinical studies on more than 230 patients over 3,800 research nights demonstrated the device's efficacy. The company received FDA clearance earlier in 2017 and is preparing for a commercial launch. Cerêve intends to use newly raised funds to build out infrastructure and support that product introduction. The company was formed in 2008 and is led by CEO Craig Reynolds; Eric Nofzinger M.D. is a founder.
- Ebb Therapeutics
Participated · Series B · Jan 2017
Cerêve’s core product is the Cerêve System, an intelligent bedside device that precisely cools and pumps fluid to a forehead pad worn throughout the night to reduce time to sleep. The device received FDA clearance and was evaluated in three independent clinical studies covering more than 230 patients and roughly 3,800 research nights, which demonstrated safety and efficacy. The company holds eight issued and 21 pending patents around the therapy and reports clinical subjects found the device easy to use and comfortable. Management includes executives with prior experience at Respironics, reflecting sleep-sector expertise. Cerêve plans a U.S. market launch in the second half of 2017 and is preparing infrastructure and commercialization activities to meet physician and patient demand. The recent financing provides capital to support those launch and expansion preparations.